← All countries · Western Pacific
68.8%
MCV1
2024 · Administrative (country-reported)
57.6%
DTP3
2024 · Administrative (country-reported)
57.5%
IPV complete
2024 · Administrative (country-reported)
60.4%
HepB3
2024 · Administrative (country-reported)
0
Measles cases
2024 reported
0
Pertussis (whooping cough) cases
2024 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 13%2010 · Administrative (country-reported) | 13% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 69.9%2024 · Administrative (country-reported) | 69.9% | D · poor | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 57.6%2024 · Administrative (country-reported) | 57.6% | D · poor | |
| IPV1First dose of inactivated polio vaccine | 69.9%2024 · Administrative (country-reported) | 69.9% | D · poor | |
| IPV completeInactivated polio vaccine, complete primary series | 57.5%2024 · Administrative (country-reported) | 57.5% | D · poor | |
| MCV1First dose of measles-containing vaccine | 68.8%2024 · Administrative (country-reported) | 68.8% | D · poor | |
| MCV2Second dose of measles-containing vaccine | 72.7%2024 · Administrative (country-reported) | 72.7% | D · poor | |
| RCV1First dose of rubella-containing vaccine | 68.8%2024 · Administrative (country-reported) | 68.8% | D · poor | |
| HepB3Third dose of hepatitis B vaccine | 60.4%2024 · Administrative (country-reported) | 60.4% | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | 81.7%2024 · Administrative (country-reported) | 81.7% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 57.0%2024 · Administrative (country-reported) | 57.0% | D · poor | |
| PCV1Pneumococcal conjugate vaccine, first dose | 58.9%2024 · Administrative (country-reported) | 58.9% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 71.3%2024 · Administrative (country-reported) | 71.3% | D · poor | |
| RotaCRotavirus vaccine, complete series | 48.4%2024 · Administrative (country-reported) | 48.4% | D · poor | |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2011 · Administrative (country-reported) | 0% | D · poor | |
| MenAMeningococcal A conjugate (meningitis belt) | 91.3%2021 · Administrative (country-reported) | 91.3% | D · poor | |
| JEJapanese encephalitis vaccine (countries at risk) | 0%2011 · Administrative (country-reported) | 0% | D · poor | |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 0%2011 · Administrative (country-reported) | 0% | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | C · weak | |
| Rubella all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | C · weak | |
| Congenital rubella syndrome all countries · vaccine evidence | 02024 | 0per 10,000 live births | D · poor | |
| Mumps all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | C · weak | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | C · weak | |
| Diphtheria all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | C · weak | |
| Tetanus (total) all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor | |
| Neonatal tetanus all countries · vaccine evidence | 02024 | 0per 1,000 live births | D · poor | |
| Polio (paralytic) all countries · vaccine evidence | 02005 | 0per 1,000,000 <15 population | no data | |
| Yellow fever all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor | |
| Japanese encephalitis all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor |
National schedule (latest WHO listing)
Show the schedule (55 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPDTaP (acellular) vaccine | 1 | W6 | General/routine | |
| DTAPDTaP (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPDTaP (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPDTaP (acellular) vaccine | 4 | M15-M18 | General/routine | |
| DTAPDTaP (acellular) vaccine | 5 | Y4-Y6 | General/routine | |
| DTAPHEPBIPVDTaP-HepB-IPV (acellular) vaccine | 1 | W6 | General/routine | |
| DTAPHEPBIPVDTaP-HepB-IPV (acellular) vaccine | 2 | M6 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 1 | W6 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y4-Y6 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | >=Y19 | Risk group(s) | This is offered to any person who is not fully vaccinated and who is at risk for hepatitis A virus infection. |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 2 | +M6 | Risk group(s) | This is offered to any person who is not fully vaccinated and who is at risk for hepatitis A virus infection. |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M12 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | +M6 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | Use monovalent HepB vaccine for doses administered before age 6 weeks |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | W6 | General/routine | Use monovalent HepB vaccine for doses administered before age 6 weeks |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M6 | General/routine | Use monovalent HepB vaccine for doses administered before age 6 weeks |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | W6 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 2 | M4 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 3 | M15-M18 | General/routine | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y9-Y14 | HPV administered to females and males | Both Male and Females are offered HPV at age 9-14 years old for the first dose. The 2nd and 3rd dose depends on when the 1st dose was administered, but usually after 6 months. Age 15 and older is offered to both males and females. The recommended 3 dose schedule is 0, 1-2 and 6 months. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | Both Male and Females are offered HPV at age 9-14 years old for the first dose. The 2nd and 3rd dose depends on when the 1st dose was administered, but usually after 6 months. Age 15 and older is offered to both males and females. The recommended 3 dose schedule is 0, 1-2 and 6 months. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 2 | >=M6 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 1 | W6 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 4 | Y4-Y6 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Y11 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | Y16 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y4-Y6 | General/routine | For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 1 | M12 | General/routine | For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | W6 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M6 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 4 | M15-M18 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | W6 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y7-Y18 | General/routine | |
| VARICELLAVaricella vaccine | 1 | M12 | General/routine | For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. |
| VARICELLAVaricella vaccine | 2 | Y4-Y6 | General/routine | For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Y50-Y85 | Adults |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.